gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Kallikrein-related peptidase 3

Prostate-Specific Antigen
Kallikreins are a subgroup of serine proteases having diverse physiological functions. Growing evidence suggests that many kallikreins are implicated in carcinogenesis and some have potential as novel cancer and other disease biomarkers. This gene is one of the fifteen kallikrein subfamily members located in a cluster on chromosome 19. Its protein product is a protease present in seminal plasma. It is thought to function normally in the liquefaction of seminal coagulum, presumably by hydrolysis of the high molecular mass seminal vesicle protein. Serum level of this protein, called PSA in the clinical setting, is useful in the diagnosis and monitoring of prostatic carcinoma. Alternate splicing of this gene generates several transcript variants encoding different isoforms. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: MEN, HAD, AGE, CAN, iMpact
Papers on Prostate-Specific Antigen
Limitations of Prostate-specific Antigen Testing After a Prostate Cancer Diagnosis.
New
Cooney et al., Ann Arbor, United States. In Eur Urol, Feb 2016
UNASSIGNED: Prostate-specific antigen (PSA) is frequently used in isolation to guide treatment decisions in men with recurrent prostate cancer, a practice discouraged by prostate cancer working groups and guidelines.
The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
New
Briganti et al., Milano, Italy. In Eur Urol, Jan 2016
OBJECTIVE: To evaluate the prognostic value of early postoperative prostate-specific antigen (PSA) levels after RP in patients with lymph node invasion (LNI).
Prostate-specific antigen kinetics after stereotactic body radiotherapy as monotherapy or boost after whole pelvic radiotherapy for localized prostate cancer.
New
Kim et al., Inch'ŏn, South Korea. In Prostate Int, Dec 2015
However, prostate-specific antigen (PSA) kinetics after SBRT has not been well characterized.
The Practicality of Targeted Prostate Biopsy Procedures on the Dominant Side of the Tumor Determined by Magnetic Resonance Imaging in Elderly Patients with High Serum Levels of Prostate-Specific Antigen.
New
Park et al., Cheju, South Korea. In World J Mens Health, Dec 2015
PURPOSE: To examine the possibility of reducing the number of cores per prostate biopsy in elderly patients with high levels of prostate-specific antigen (PSA) without significantly lowering the detection rate of prostate cancer.
Prostate-specific Antigen (PSA) Density and Free to Total PSA Ratio in Diagnosing Prostate Cancer with Prostate-Specific Antigen Levels of 4.0 ng/ml or Less.
New
Li et al., Nanzhou, China. In Iran J Public Health, Nov 2015
BACKGROUND: We aimed to value the usefulness of free to total prostate-specific antigen and Prostate-specific antigen (PSA) density for prostate cancer in the patients with PSA levels of 4.0 ng/ml or less.
National Prostate Cancer Screening Rates After the 2012 US Preventive Services Task Force Recommendation Discouraging Prostate-Specific Antigen-Based Screening.
New
Impact
Eggener et al., Chicago, United States. In J Clin Oncol, Sep 2015
PURPOSE: In 2012, the US Preventive Services Task Force (USPSTF) discouraged prostate-specific antigen (PSA) -based prostate cancer screening.
Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status.
Review
New
Matin et al., Barretos, Brazil. In Urology, Jul 2015
Prostate-specific antigen testing and magnetic resonance imaging led to PC detection in a much earlier stage.
Prostate-specific antigen-based prostate cancer screening: Past and future.
Review
New
Roobol et al., Rotterdam, Netherlands. In Int J Urol, Jun 2015
Prostate-specific antigen-based prostate cancer screening remains a controversial topic.
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
Review
Tawfik, In Ont Health Technol Assess Ser, 2014
BACKGROUND: The prostate-specific antigen (PSA) blood test has become widely used in Canada to test for prostate cancer (PC), the most common cancer among Canadian men.
Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Evidence-Based Analysis.
Review
Pron, In Ont Health Technol Assess Ser, 2014
Prostate-specific antigen (PSA) testing for PC has been in common practice for more than 20 years.
Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.
Review
Chun et al., Hamburg, Germany. In Adv Exp Med Biol, 2014
Due to low specificity of Prostate-Specific Antigen (PSA) we face a certain risk of overdiagnosis and overtreatment of Prostate Cancer (PCa).
Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
Impact
Small et al., Durham, United States. In J Clin Oncol, 2013
PURPOSE: Prostate-specific antigen (PSA) kinetics, and more specifically a ≥ 30% decline in PSA within 3 months after initiation of first-line chemotherapy with docetaxel, are associated with improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC).
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer.
Impact
Scher et al., San Diego, United States. In J Clin Oncol, 2013
Prostate-specific antigen declines at 12 weeks (≥ 50% reduction from baseline) were observed in 46.7% of patients.
Effectiveness of the combined evaluation of KLK3 genetics and free-to-total prostate specific antigen ratio for prostate cancer diagnosis.
GeneRIF
Plebani et al., Padova, Italy. In J Urol, 2012
Prostate specific antigen correlated with KLK3 genetics (rs2735839 polymorphism p = 0.001, and rs2569733, rs2739448 and rs925013 haplotype combination p = 0.003).
Effect of CYP17 and PSA gene polymorphisms on prostate cancer risk and circulating PSA levels in the Slovak population.
GeneRIF
Kliment et al., Martin, Slovakia. In Mol Biol Rep, 2012
Our study did not provide support for the hypothesized relationship between CYP17 and PSA gene polymorphisms and prostate cancer in the Slovak male population.
Long terminal repeats act as androgen-responsive enhancers for the PSA-kallikrein locus.
GeneRIF
Clements et al., Australia. In Endocrinology, 2012
Long terminal repeats act as androgen-responsive enhancers for the PSA-kallikrein locus
Inverse relationship between PSA and IL-8 in prostate cancer: an insight into a NF-κB-mediated mechanism.
GeneRIF
St Clair et al., Lexington, United States. In Plos One, 2011
RelB plays a critical role in the response of PCa to radiotherapy and the inverse expression of IL-8 and PSA
Evaluation of the effects of androgen receptor gene trinucleotide repeats and prostate-specific antigen gene polymorphisms on prostate cancer.
GeneRIF
Tansug et al., Adana, Turkey. In Genet Mol Res, 2011
CAG and GGC repeats in the AR and PSA gene polymorphisms may be associated with prostate cancer risk and BPH in the Turkish population.
mRNA expression signature of Gleason grade predicts lethal prostate cancer.
Impact
Mucci et al., Boston, United States. In J Clin Oncol, 2011
PURPOSE: Prostate-specific antigen screening has led to enormous overtreatment of prostate cancer because of the inability to distinguish potentially lethal disease at diagnosis.
Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program.
Impact
Walsh et al., Baltimore, United States. In J Clin Oncol, 2010
PURPOSE: To assess the predictive ability of prostate-specific antigen (PSA) velocity (PSAV) and doubling time (PSADT) for biopsy progression and adverse pathology at prostatectomy among men with low-risk prostate cancer enrolled on an active-surveillance program.
share on facebooktweetadd +1mail to friends